Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Fineline Cube Aug 21, 2026
Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Fineline Cube Aug 21, 2026
Company Drug

Taiwan FDA Reviews Nefecon New Drug Application from Everest Medicines

Fineline Cube Dec 27, 2023

China-based Everest Medicines (HKG: 1952) has announced that the New Drug Application (NDA) for Nefecon...

Company Deals

J&J’s Janssen Secures Exclusive Global Rights to Develop LCB84 ADC from LegoChem Biosciences

Fineline Cube Dec 27, 2023

Johnson & Johnson’s (J&J; NYSE: JNJ) pharmaceutical subsidiary, Janssen, has entered into an exclusive global...

Company Deals

BMS Expands Oncology Portfolio with $4.1 Billion RayzeBio Acquisition

Fineline Cube Dec 27, 2023

Bristol Myers Squibb (BMS; NYSE: BMY) has announced the acquisition of RayzeBio (NASDAQ: RYZB), a...

Company Drug

Amgen’s Lumakras Faces Full Approval Delay as FDA Requests New Study

Fineline Cube Dec 27, 2023

The US Food and Drug Administration (FDA) has declined to grant full approval for Amgen’s...

Policy / Regulatory

China’s NMPA Proposes Enhanced IT and Visualization Requirements for Blood Product GMP

Fineline Cube Dec 27, 2023

The National Medical Products Administration (NMPA) of China is currently soliciting public feedback on the...

Company Medical Device

Fresenius Medical Care Expands Dialysis Solutions in China with 6008 CARESystem Launch

Fineline Cube Dec 27, 2023

Fresenius Medical Care AG has announced the official launch of its 6008 CARESystem hemodialysis filtration...

Policy / Regulatory

China Charts Course for Advanced Disease Prevention and Control System by 2030

Fineline Cube Dec 27, 2023

China’s State Council has issued the “Guiding Opinions on Promoting the High Quality Development of...

Company Deals

Innovent Biologics Partners with Sanegene Bio USA to Develop Hypertension Drug

Fineline Cube Dec 27, 2023

China-based Innovent Biologics (HKG: 1801) has entered into a partnership with Sanegene Bio USA Inc....

Company Drug

Guangdong Zhongsheng Pharmaceutical’s ZSP1273 for Influenza A Accepted for Review by NMPA

Fineline Cube Dec 27, 2023

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a Chinese pharmaceutical company, has announced that China’s...

Company Drug

Konruns Pharmaceutical Receives NMPA Go-Ahead for KC1036 Esophageal Cancer Study

Fineline Cube Dec 27, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has received approval from the National Medical Products...

Company Deals

Jianzhijia Health-Chain to Purchase Local Drug Retailer for $23.5 Million

Fineline Cube Dec 27, 2023

Yunnan Jianzhijia Health-Chain Co, Ltd (SHA: 605266), a Chinese healthcare company, has announced plans to...

Company Drug

Simcere Affiliate Shanghai Simnova Biotech Gets China Nod for CAR-T Therapy SNC109

Fineline Cube Dec 27, 2023

Shanghai Simnova Biotech Co., Ltd, known as Simnova outside of China and an affiliate of...

Company Deals

Biocytogen and Lepu Biotechnology Develop WT1-Targeted Trispecific Antibody for Cancer Treatment

Fineline Cube Dec 27, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) and Lepu Biotechnology Co., Ltd (HKG: 2157) have...

Company Deals

Aidea Pharmaceutical Co. Terminates ACC006 Technology Transfer Deal with Lixin Bio

Fineline Cube Dec 27, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has resolved to terminate its technology transfer agreement...

Company Deals

AstraZeneca to Acquire China’s Gracell Biotechnologies in $1.2 Billion Deal

Fineline Cube Dec 26, 2023

Pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced its intention to fully acquire Gracell Biotechnologies...

Policy / Regulatory

China’s NHC Releases Third List of Recommended Generic Drugs for Development

Fineline Cube Dec 26, 2023

The National Health Commission (NHC) of China has released its third list of drugs recommended...

Company Drug

FDA Grants Priority Review to MSD and Daiichi Sankyo’s ADC for Lung Cancer

Fineline Cube Dec 26, 2023

The US Food and Drug Administration (FDA) has accepted under priority review a filing from...

Company Deals Drug

AbbVie and Alpine Immune Sciences Halt Early Enrollment in Lupus Trial

Fineline Cube Dec 26, 2023

AbbVie (NYSE: ABBV) and Alpine Immune Sciences (SWX: ALPN) have made the decision to prematurely...

Policy / Regulatory

Jiangsu Province Announces Dual Channel Management and Separate Payment Drug List

Fineline Cube Dec 26, 2023

Jiangsu province’s healthcare security administration has released a list identifying drugs subject to dual channel...

Company Drug

J&J’s Rybrevant-Lazertinib Combo Accepted for FDA Review in NSCLC

Fineline Cube Dec 26, 2023

The US Food and Drug Administration (FDA) has accepted for review Johnson & Johnson’s (J&J;...

Posts pagination

1 … 469 470 471 … 711

Recent updates

  • CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors
  • LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval
  • China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect
  • Boehringer Ingelheim Upgrades China Strategy with New Shanghai R&D Center, Deepening Investment in Pharma and Animal Health
  • Ultomiris Wins NMPA Approval for PNH in China, Bringing Long‑Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Company

Boehringer Ingelheim Upgrades China Strategy with New Shanghai R&D Center, Deepening Investment in Pharma and Animal Health

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.